Andrew Joe

Andrew Joe is a seasoned medical professional currently serving as Chief Medical Officer for Mestag Therapeutics and an Advisory Board Member for Octozi. Andrew holds a longstanding position as an Assistant Professor at Columbia University Medical Center since 1999. Andrew has previously consulted for Merus N.V., where significant contributions included the FDA BLA submission for Bizengri and the initiation of clinical trials for Petosemtamab. Andrew's past roles include Vice President of Oncology Development at Sanofi, Executive Director at Merck, Senior Medical Director at Novartis Pharmaceuticals, and Medical Director at Hoffmann-La Roche, where key achievements involved leading major oncology drug developments and securing global approvals. Andrew earned a Bachelor of Science in Chemistry and Biology from the Massachusetts Institute of Technology and a Doctor of Medicine from the Icahn School of Medicine at Mount Sinai.